BioSpace News Archive

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that Cigna has added EYSUVIS

Amgen announced today that it has entered into a multi-year partnership with Mila – Quebec Artificial Intelligence Institute. One of the world’s leading biotechnology companies, Amgen uses cutting-edge science and technology to discover and develop innovative therapeutics, and AI is currently deployed in several of its R&D and manufacturing activities

Cytocom, Inc., a leading biopharmaceutical company creating next generation immune therapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety and efficacy of CYTO-205 as a treatment to slow or halt the progression of SARS-CoV-2,

Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of oncology, is excited to announce it has expanded its Strategic Alliance Partnership (SAP) program with the addition of the Kentucky Society of Clinical Oncology and Virginia Cancer Specialists, strengthening its position in the oncology space

ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent achievement of a significant milestone - enrollment of 100 patients in its U.S. based VENT-AVOID pivotal trial.

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the year ended December 31, 2020 after the market close on Thursday, March 25, 2021

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its fourth quarter 2020 financial results after the market closes on Tuesday, March 30, 2021.

Preparing to submit a 510(k) application to FDA by Q3 2021 for Pure-Vu System indication expansion for Upper GI endoscopies

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the fourth quarter ended December 31, 2020. As of December 31, 2020, cash, cash equivalents and investments totaled $115.2 million.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the three and twelve months ended December 31, 2020 and introduced financial guidance expectations for fiscal year ended December 31, 2021.